Successful development and clinical translation of CAR-NK therapies starts at the source— high-quality leukopaks collected from well-characterized donors are essential to mitigate risks and delays. Read our latest blog to learn more:?https://lnkd.in/e5eY25QG #celltherapy #leukpak #NKcells?
AllCells
生物技术研究
Alameda，California 8,729 位关注者
Providing the highest quality, healthy human primary cells for research.
关于我们
Founded in 1998, AllCells, a Discovery Life Sciences brand, is a market-leading provider of highly characterized primary cell and tissue products, supporting global biomedical organizations seeking to develop and manufacture novel drugs and cell therapies. By providing Clinical Grade and RUO products, custom donor management services, and integrated analytical capabilities, AllCells' comprehensive solutions streamline every stage of development to help bring novel therapies to market faster. Our FDA-registered, IRB-approved, AABB-compliant donor facilities strategically located across the U.S. provide access to healthy, recallable, well-characterized donors with diverse and rare demographics. Our adjacently located processing facilities enable immediate processing, cryopreservation, and a high degree of responsiveness to accommodate custom requests with exceptional quality and deliverability. Backed by over 30 years of combined scientific and regulatory expertise, AllCells is committed to providing flexible and scalable solutions necessary to dynamic, client-specific needs and timelines from inception to commercialization. AllCells – Science at your Service?
- 网站
-
https://www.allcells.com/
AllCells的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Alameda，California
- 类型
- 私人持股
- 创立
- 1998
- 领域
- Human Primary Cells、Stem Cells、PBMCs、GMP Allogeneic Clinical Grade Primary Cells、Bone Marrow、Leukopak、Mobilized Leukopak、Cord Blood和CD34+ Stem cells
地点
AllCells员工
动态
-
Granulocyte contamination in leukopaks is a major issue in CAR-T cell development, affecting T cell expansion, functionality, and clinical efficacy. Granulocyte contamination and leukopak quality are closely linked, and smart donor selection combined with optimized leukapheresis protocols can significantly enhance overall quality.? Read our new blog post to learn more: https://lnkd.in/eNEiC3eA #celltherapy #leukpak #CART?
-
The recording of our LinkedIn Live “Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing Workflow” is now available. Watch the replay here: https://lnkd.in/gVz6HYT3 To learn more about GMP Cryopreserved PBMCs, visit our website: https://lnkd.in/g323KhT7?
-
Join us today for an insightful LinkedIn Live session with Dr. Yuki Kato Maves who will present a real-world case study highlighting how we partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs). https://lnkd.in/gqebDYXG See you at 3pm ET / 12pm PT!?
Join us for this live event! #CellTherapy #GeneTherapy #Immunotherapy #GMP
Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing
www.dhirubhai.net
-
Our Alameda, California site is now AABB-accredited!
We are pleased to announce that our Alameda, California site is now AABB-accredited. This internationally recognized accreditation signifies that Discovery Life Sciences adheres to globally recognized standards for optimal safety, quality, and ethical practices concerning patients, donors, and recipients of blood and cellular therapies. Our commitment to excellence encompasses every step of the process —from collection and processing to storage and distribution of hematopoietic progenitor cells (HPCs), ensuring the highest industry standards. For inquiries regarding your cell and gene therapy development needs, please contact us today. We look forward to collaborating with you. https://lnkd.in/gEChYJu3 #AABB #CellTherapy #GeneTherapy #CGT #Immunotherapies?
-
-
How did Discovery’s initiative with a CGT developer significantly reduce the risk of failure and CDMO costs? Tune into our upcoming LinkedIn Live event on 11/13, where Dr. Yuki Kato Maves will present a real-world case study highlighting how we partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs), resulting in cost and risk reductions. Register now: https://lnkd.in/gqebDYXG
Join us for this live event! #CellTherapy #GeneTherapy #Immunotherapy #GMP
Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing
www.dhirubhai.net
-
Are you planning to attend the 6th TIL Therapies Summit at the Colonnade Hotel in Boston next week? Schedule a meeting with us to learn more about how AllCells RUO and GMP products can help advance the tumor-infiltrating lymphocyte therapy development.? Schedule a Meeting: https://lnkd.in/eeUYKCPp Connect with Conor Marino for more information.?
-
-
Are you attending Meeting on the Mesa in Phoenix, Arizona next week? Our CGT experts are excited to meet with you! Learn more about our AllCells RUO and GMP products by arranging a meeting on the Partnering One portal, or connect with the team directly below:? James Buto, MS, Angela Martinovic, Karen Bostwick We look forward to seeing you!? #CGMesa24 Alliance for Regenerative Medicine
-
-
There is still time to visit us at Booth 38 during the #CARTCRSummit at the Boston Hynes Convention Center.? Here are also a few snaps of the team, and a great speaking session presented by Yuki Kato Maves, PhD, Associate Director of Product Management.? Karen Bostwick, Conor Marino, Angela Martinovic, McLean Collins, Andy L. Chiang
-